Unicycive Therapeutics, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a separate Q4 report; the filing does not provide standalone fourth-quarter financial results. Unicycive is a clinical-stage biotechnology company developing kidney-disease therapies and had no commercial product sales.
Financial performance and liquidity
| Metric | FY 2022 / Dec. 31, 2022 | FY 2021 / Dec. 31, 2021 |
|---|---|---|
| Revenue | $951,000 licensing revenue | None |
| Research and development expense | $12.436 million | $6.080 million |
| General and administrative expense | $6.567 million | $2.897 million |
| Total operating expenses | $19.003 million | $8.977 million |
| Net loss | $18.058 million; $1.20 per share | $10.017 million; $0.86 per share |
| Cash used in operating activities | $15.651 million | $5.767 million |
| Cash | $455,000 | $16.579 million |
| Total assets | $2.818 million | $18.744 million |
| Total liabilities | $3.284 million | $2.260 million |
There were no product sales, so product gross margin is not applicable. The company’s $951,000 revenue came from an upfront Renazorb license payment from Lee’s Pharmaceutical. Operating expenses more than doubled year over year, principally reflecting increased development activity and staffing. The net loss widened by 80%.
At year-end, current assets were $2.644 million and current liabilities were $3.284 million, implying a working-capital deficit of approximately $640,000. Liabilities included accounts payable, accrued liabilities and operating lease obligations; the filing reports no outstanding convertible notes at year-end. Accumulated deficit was $33.997 million. The company reported no cash dividends paid during 2022.
After year-end, a March 2023 private placement provided approximately $30 million in initial gross funding, or $28.1 million net proceeds, within a financing structure that could provide up to $130 million gross. Management said post-financing resources were expected to fund operations for at least 12 months from the filing date. The financing includes preferred stock and warrants and could result in substantial dilution; conversion is subject to stockholder approval.
Business progress, outlook and risks
- Renazorb: The lead candidate targets hyperphosphatemia in dialysis patients with chronic kidney disease. A bioequivalence study found similar urinary phosphorus reduction to Fosrenol and concluded the products were bioequivalent. Following a March 2022 Type C meeting, the FDA confirmed that the bioequivalence study and previously agreed toxicology study could support an NDA under the 505(b)(2) pathway; the company reported that no further clinical studies were required for the NDA. The candidate was not approved as of the reporting period.
- UNI-494: The acute kidney injury candidate remained in development. The UK MHRA accepted the company’s CTA for a Phase 1 study in healthy volunteers. The company planned to submit a corresponding U.S. IND in 2024 for a potential Phase 2 proof-of-concept study; this is a plan, not a commitment or guarantee.
- Partnerships: Lee’s received exclusive Renazorb rights in China, Hong Kong and certain Asian markets, with a $1 million upfront payment, potential milestones and tiered royalties. A Korea license with Lotus was signed in February 2023, after year-end, for a $750,000 upfront payment and potential milestones and royalties.
- Commercial and reimbursement outlook: The company described U.S. launch options including self-commercialization, partnering or distribution through dialysis organizations. CMS scheduled inclusion of oral hyperphosphatemia drugs in the ESRD dialysis payment bundle for 2025, with a transitional separate-payment period expected for at least two years. Timing, reimbursement and commercial uptake remain uncertain. No quantified company revenue or earnings guidance was provided.
- Capital and execution risks: The company has incurred recurring losses, expects losses to continue and will need additional capital. Development, regulatory review, manufacturing, market acceptance, reimbursement and competition could delay or prevent commercialization. Renazorb also depends on contract manufacturing; UNI-494 depends on a third-party license.
- Unusual and governance matters: Management reported ineffective disclosure controls and a material weakness in internal control over financial reporting, citing insufficient accounting staff and expertise. It planned remediation by the end of 2023. The auditor issued an unqualified opinion on the financial statements but was not engaged to audit internal-control effectiveness. In March 2023, Nasdaq notified the company that it had regained compliance with the minimum bid-price requirement. The company also disclosed that substantially all cash had been held at Silicon Valley Bank; it regained access on March 13, 2023 following government action.
Important facts for investors to verify
- Latest cash balance, operating burn and runway after the March 2023 financing; confirm how much of the potential $130 million financing was actually funded and the conditions attached to future tranches.
- Stockholder approval status, conversion and warrant terms, and the resulting fully diluted share count and investor voting influence.
- Renazorb NDA submission and FDA review status, and whether any additional studies or regulatory requirements have emerged.
- UNI-494 Phase 1 progress and the status and timing of any U.S. IND or Phase 2 plans.
- Progress on remediating the material weakness, plus any subsequent changes to liquidity, reimbursement rules, manufacturing arrangements or commercial partnerships.